High frequency of the expanded C9ORF72 hexanucleotide repeat in familial and sporadic Greek ALS patients. by Mok, KY et al.
(Neurobiology of Aging 33 (2012) 1851.e1–1851.e5High frequency of the expanded C9ORF72 hexanucleotide repeat in
familial and sporadic Greek ALS patients
Kin Y. Moka,1, Georgios Koutsisa,b,1, Lucia V. Schottlaendera, James Polkea, Marios Panasb,
Henry Houldena,c,*
a Department of Molecular Neuroscience, UCL Institute of Neurology,London, UK
b Neurogenetics Unit, Department of Neurology, University of Athens Medical School, Eginitio Hospital, Athens, Greece
c MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery,London, UK
Received 29 January 2012; received in revised form 19 February 2012; accepted 19 February 2012
Abstract
An intronic expansion of a hexanucleotide GGGGCC repeat in the C9ORF72 gene has recently been shown to be an important cause of
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in familial and sporadic cases. The frequency has only been defined
in a small number of populations where the highest sporadic rate was identified in Finland (21.1%) and the lowest in mainland Italy (4.1%).
We examined the C9ORF72 expansion in a series of 146 Greek ALS cases, 10.95% (n  16) of cases carried the pathological expansion
defined as greater than 30 repeats. In the 10 familial ALS probands, 50% (n  5) of them carried a pathologically large expansion. In the
remaining 136 sporadic ALS cases, 11 were carriers (8.2%). None of the 228 Greek controls carried an expanded repeat. The phenotype
of our cases was spinal (13/16) or bulbar (3/16) ALS, the familial cases were all spinal ALS and none of our cases had behavioral
frontotemporal dementia. Expansions in the C9ORF72 gene therefore represent a common cause of ALS in Greece and this test will be
diagnostically very important to implement in the Greek population. The frequency is higher than other populations with the exception of
Finland and this may be due to Greece being a relatively isolated population.
© 2012 Elsevier Inc. All rights reserved.
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Amyotrophic lateral sclerosis (ALS) is a progressive
neurodegenerative disorder characterized by degeneration
of the brain and spinal cord leading to weakness, wasting,
bulbar problems, and usually death within 3 years (Clarke et
al., 2009). Originally noted in an essay in 1830 by Charles
Bell the disorder has been described throughout the world
with an ALS incidence of between 1.7 and 8.2 people per
100,000 in populations in Europe and the United States, the
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10.1016/j.neurobiolaging.2012.02.021lowest incidence being in Italy (Turin) (Leone et al., 1983)
and highest in Finland (Beghi et al., 2011; Cronin et al.,
2007; Logroscino et al., 2010; Murros and Fogelholm,
1983). Approximately 10% of ALS cases are familial, and
genetic defects have been identified in approximately a third
of families (Rohrer and Warren, 2011; Valdmanis and Rou-
leau, 2008; Vance et al., 2006) and a small percentage of
sporadic cases, in an ever-increasing number of genes that
include: superoxide dismutase 1 (SOD1) (Rosen et al.,
1993), transactivation response (TAR) DNA binding pro-
tein (TARDBP) (Sreedharan et al., 2008), fused in sarcoma
(FUS) (Kwiatkowski et al., 2009), valosin-containing pro-
tein (VCP) (Johnson et al., 2010), factor-induced gene 4
(FIG4) (Chow et al., 2009), angiogenin (ANG) (Greenway
et al., 2006), ubiquillin 2 (UBQLN2) (Deng et al., 2011),









































1851.e2 K.Y. Mok et al. / Neurobiology of Aging 33 (2012) 1851.e1–1851.e5More than 10 years ago, a locus for autosomal dominant
familial ALS and frontotemporal dementia was identified on
chromosome 9p21 (Morita et al., 2006). This region was
refined to a common 140 kb haplotype containing 3 genes,
MOBKL2B, C9orf72, and IFNK that were extensively in-
vestigated (Laaksovirta et al., 2010; van Es et al., 2009).
Two research groups identified a pathogenic GGGGCC
hexanucleotide repeat expansion in intron-1 of the
C9ORF72 gene as an important cause for both familial and
sporadic ALS (DeJesus-Hernandez et al., 2011; Renton et
al., 2011). They found the expansion (greater than 30 re-
peats) was present in 46.4% of familial ALS and 21% of
sporadic ALS cases from Finland and between 28.5% and
38% familial ALS in series from Italy, Germany, and the
United States (Orr, 2011). The expanded repeat was absent
in US, Italian, and German controls but present at a rate of
0.4% in Finnish controls. In the UK, pathological expan-
sions accounted for 50% (26/52) of familial and 7% (35/
496) of sporadic ALS (Cooper-Knock, 2012). Further anal-
ysis of the incidence in sporadic ALS suggests a marked
difference across Europe (north to south), the highest prev-
alence being in Finland (21.1%), then the UK (7%), then
Germany (5.2%), Belgium (5%), and the lowest in Italy at
4.1% (Cooper-Knock, 2012; DeJesus-Hernandez et al.,
2011; Gijselinck et al., 2012; Renton et al., 2011; Traynor,
B.J., personal communication, C9ORF72 hexanucleotide
repeat expansion in sporadic ALS and FTD around the
world, 2012). Sardinia is likely to have a higher prevalence,
but this is an unusual isolated population which also con-
tains a high frequency of TARDBP mutations (Chiò et al.,
2011). The overall incidence of ALS may suggest a founder
expansion, disseminated by a traveling population such as
the Vikings or it could be accounted for by population-
specific effects such as isolation. Clinically, the C9ORF72
expansion causes a frontotemporal dementia (FTD), and an
ALS with phenotype is often associated with cognitive prob-
lems compared with unexpanded patients. Neuropathologi-
cally, abnormal subcellular localization and aggregation of
TAR DNA binding protein 43 (TDP-43) is found widely
distributed in most patients with ALS and FTD, cortical
lesions are TDP-43 positive but cerebellar lesions are
negative (Al-Sarraj et al., 2011; Ince et al., 2011; Stewart
et al., 2012). These findings further highlight the impor-
tance of TDP-43 in FTD and ALS.
There are no further data available on the frequency and
phenotype of C9ORF72 expansions in other European or
editerranean populations. We therefore examined the fre-
uency, spectrum, and phenotype of patients with an ex-
anded C9ORF72 hexanucleotide repeat in a well-defined
series of ALS cases and controls from Greece.
2. Methods
DNA was extracted from 146 ALS cases and 228 con-
trols consecutively collected from the Neurology Depart- rment of the University of Athens, Greece. The study was
ethically approved with informed consent from patients
taking part who were diagnosed according to the El Escorial
criteria (Brooks et al., 2000). We screened the C9ORF72
GGGGCC expansion in the ALS cohort and the controls
using the reversed-prime polymerase chain reaction (PCR)
protocol as previously reported (Renton et al., 2011).
Briefly, 100 ng of genomic DNA was amplified with a final
volume of 20 L containing 10 L FastStart PCR Master-
ix (Roche, Foster City, CA, USA), 0.18 mM 7-deaza
GTP, 1xQiagenQ solution, 10% dimethyl sulfoxide
DMSO), 0.7 M reverse primer consisting of 4 GGGGCC
epeats and an anchor tail (TACGCATCCCAGTTT-
AGACGGGGGCCGGGGCCGGGGCCGGGG), 1.4 M
6FAM-fluorescent-primer located 280 base pairs 3= prime to
the repeat sequence (AGTCGCTAGAGGCGAAAGC) and
1.4 M anchor primer corresponding to the anchor tail of
he reverse primer (TACGCATCCCAGTTTGAGACG). A
ouchdown PCR cycling protocol was used where the initial
nnealing temperature was lowered from 70 °C to 56 °C in
°C increments and a 3-minute extension time for each
ycle (Paisán-Ruiz et al., 2012). Fragment length analysis
as performed on an ABI 3730XL genetic analyzer (Ap-
lied Biosystems, Inc., Foster City, CA, USA), analyzed
sing ABI GeneScan v 3.7 (Applied Biosystems, Inc., Fos-
er City, CA, USA).
. Results
Overall, 10.95% (n  16) of ALS cases carried the
9ORF72 pathological expansion (defined as  30 re-
eats). In the 146 ALS cases, 10 were familial ALS pro-
ands, 50% (n  5) of them carried a pathologically large
xpansion. In the remaining 136 sporadic ALS, 11 were
arriers (8.2%) (Table 1). There was no significant differ-
nce in gender, age, and age/site of onset between expan-
ion carriers and noncarriers; there was also no significant
ifference in the age of onset between patients with and
ithout expansions (Table 1, Fig. 1). No expansions were
een in controls. The cumulative frequency on the age of
nset suggested that penetrance is about 50% at 55 years old
nd almost complete penetrance at 75 (Fig. 1). The pheno-
ype of the familial and sporadic ALS cases was either
pinal upper or lower limb onset (13/16) or bulbar (3/16)
nset, the age of onset ranged between 25 and 73 years. In
amilial ALS, there were no bulbar onset cases and a greater
reponderance of female cases (Table 1 and Supplementary
able 1).
. Discussion
The identification of C9ORF72 expansions in ALS and
TD has been an extremely important discovery that will
orm an essential common diagnostic test in ALS and FTD
nd also strengthen the link to TDP-43 (Orr, 2011). We











1851.e3K.Y. Mok et al. / Neurobiology of Aging 33 (2012) 1851.e1–1851.e5a cohort of Greek ALS patients revealing a relatively high
prevalence of expanded repeats in the Greek sporadic ALS
population (8.2%). This is the highest sporadic figure out-
side of Finland reported to date. These data support the
pathological expansion as an important cause of ALS that
extends to Mediterranean populations. A further interesting
point is that the majority of Greek cases with expansions
have a spinal onset, much higher than in the previous reports
where the proportion of bulbar onset cases was much higher
(DeJesus-Hernandez et al., 2011; Renton et al., 2011).
Table 1
Demographic and C9ORF72 repeat data from the Greek ALS cases
Total cohort Familial Sporadic
n (%) 146 10 (6.8) 136 (93.2)
Age as of 01/01/12 (y
 SD)
59.1  13.0 50.8  12.2 59.7  12.9
Male 108 (74.0) 4 (40.0) 104 (76.5)
emale 38 (26.0) 6 (60.0) 32 (23.5)
ge at onset of ALS
(y  SD)
57.3  13.0 49.7  11.1 57.9  12.9
Mode of onset (%)
Spinal 106 (75.2) 10 (100.0) 96 (73.3)
Bulbar 35 (24.8) 0 (0.0) 35 (26.7)
9ORF72 repeat (%)
Expanded 16 (11.0) 5 (50.0) 11 (8.1)
Nonexpanded 130 (89.0) 5 (50.0) 125 (91.9)
Missing data from 5 sporadic patients.
Key: ALS, amyotrophic lateral sclerosis.
a t test, familial versus sporadic.
b Fisher exact test, 2-sided p value, familial versus sporadic; using a t tes
age at onset.
Fig. 1. Cumulative frequency of the age of onset in C9ORF72 expansion
rcarriers.The 50% prevalence of the expansion within Greek fa-
milial ALS is congruent with previous reports. Previously
we have reported the likely common founder effect origi-
nating from Scandinavia. Haplotypes in the ALS cases from
other populations (USA and Italy) also carry part of the
Finnish haplotype and it would be extremely interesting to
further define the haplotype that harbors the mutation in the
Greek population. The high frequency of expansions in the
Greek population is not consistent with the reported de-
creasing frequency of expanded repeats in ALS when trav-
eling south across Europe where frequencies consist of
Finland (21.1%), UK (7%), Germany (5.2%), Belgium
(5%), and Italy at 4.1% (Cooper-Knock, 2012; DeJesus-
Hernandez et al., 2011; Gijselinck et al., 2012; Renton et al.,
2011; Traynor, B.J., personal communication, C9ORF72
hexanucleotide repeat expansion in sporadic ALS and FTD
around the world, 2012). These frequencies are similar to
the overall distribution of ALS in these countries. It has
been suggested the ALS haplotype could be accounted for
by the Vikings, but Viking influence was limited in Greece.
A more plausible explanation is the relatively isolated na-
ture of the Greek population over recent centuries with low
values of past and present racial admixture. This explana-
tion may underlie the high frequency of the ALS haplotype
in Finland, which also has a relatively isolated population
and a high frequency of ALS and the C9ORF72 expansion.
he high frequency of expansions in apparently sporadic
ndividuals is difficult to explain but is likely due to lack of
amily history information or previous generations dying
arly before the expansion caused disease. Another expla-
ation is reduced penetrance of the expansion, and a further
uestion is whether this pathogenic expansion goes through





16 (11.0) 130 (89.0) 5 (50.0) 11 (8.1)
5 a 56.4  12.2 59.5  13.1 57.2  12.6 56.1  12.6
0 b 12 (75.0) 96 (73.8) 2 (40.0) 10 (90.9)
4 (25.0) 34 (26.2) 3 (60.0) 1 (9.1)
5a 55.1  12.1 57.6  13.1 55.6  12.0 54.8  12.7
7 b 13 (81.2) 93 (74.4) 5 (100.0) 8 (72.7)
3 (18.8) 32 (25.6) 0 3 (27.3)
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1851.e4 K.Y. Mok et al. / Neurobiology of Aging 33 (2012) 1851.e1–1851.e5and Zoghbi, 2007). Although we detected a small number of
cases with 20–24 repeats (4/228  1.8%) in the control
Greek population this frequency is not significantly differ-
ent when compared with 2 UK control series (unpublished
1/85  1.2% and 6/361  1.7%).
In summary, we have shown that the pathogenic
GGGGCC hexanucleotide repeat expansion in C9ORF72 is
n important cause of ALS in the Mediterranean Greek
opulation in the familial and sporadic forms of disease.
he frequency is high, second only to the Scandinavian
opulation and this suggests the repeat prevalence in
reece, and likely in the Scandinavian countries is a con-
equence of population isolation and little racial admixture.
he frequency also highlights the importance of establish-
ng C9ORF72 as a diagnostic test in familial and sporadic
atients.
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